Lauren Hackett named deputy director of administration at Albert Einstein Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Lauren Hackett was named deputy director of administration of Albert Einstein Cancer Center and associate vice president of cancer medicine at Montefiore Medicine. 

Hackett, who is currently the chief operating officer at the Allen Institute, will assume these roles in August 2021.  

At AECC, Hackett will have oversight and authority over the administrative team and structure, running all aspects of its operations. A key part of her role is partnering with the senior leaders at AECC, Einstein, and Montefiore to align and implement strategic priorities across its cancer enterprise.  

As COO at the Allen Institute, a private, non-profit research institute, she led the institute through the COVID-19 pandemic and co-developed the institute’s diversity, equity, and inclusion initiative. She also partnered with colleagues to integrate scientific strategy and planning efforts throughout administration and operations teams across the institute.  

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login